The 20–30% of central cartilaginous tumours without an IDH1/2 mutation highlights the need for additional prognostic biomarkers for patients whose tumours are WT for IDH1, IDH2 and GNAS mutations. This evidence concerns the gene IDH2 and neoplasm.